Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials

Click to increase image sizeClick to decrease image size

Declaration of interest

Sylvia Boesch received investigator fees from REATA and VICO Therapeutics. Elisabetta Indelicato is supported by the European Joint Programme on Rare Diseases (EJP-RD WP17 research mobility fellowship) and received funding by the Friedreich’s Ataxia Research Alliance (FARA), FARA Ireland, and FARA Australia as well as by the intramural funding program of the Medical University Innsbruck for young scientists MUI-START, Project 2022-1-3. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Sylvia Boesch and Elisabetta Indelicato are member of the European Reference Network for Rare Neurological Diseases—Project ID No 739510.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.